{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:17:04Z","timestamp":1781770624432,"version":"3.54.5"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100016650","name":"Rare Diseases Clinical Research Network","doi-asserted-by":"publisher","award":["NIH U54 NS115054."],"award-info":[{"award-number":["NIH U54 NS115054."]}],"id":[{"id":"10.13039\/100016650","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10072-025-08570-4","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:16:49Z","timestamp":1759796209000},"page":"7057-7060","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Two paths for turning the tide: complement and FcRn inhibition to overcome refractory myasthenia gravis"],"prefix":"10.1007","volume":"46","author":[{"given":"Silvia","family":"Falso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Morroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6270-0956","authenticated-orcid":false,"given":"Raffaele","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"8570_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM (2019) Myasthenia Gravis. Nat Rev Dis Primers. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"key":"8570_CR2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","volume":"11","author":"ML Fichtner","year":"2020","unstructured":"Fichtner ML, Jiang R, Bourke A, Nowak RJ, O\u2019Connor KC (2020) Autoimmune pathology in myasthenia Gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front Immunol 11:776. https:\/\/doi.org\/10.3389\/fimmu.2020.00776PMID: 32547535; PMCID: PMC7274207","journal-title":"Front Immunol"},{"issue":"2","key":"8570_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","volume":"20","author":"Iorio Raffaele","year":"2024","unstructured":"Iorio Raffaele (2024) Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nat Rev Neurol 20(2):84\u201398","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"8570_CR4","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/nejmoa1311084","volume":"370","author":"Jichi Nishimura","year":"2014","unstructured":"Nishimura Jichi, Yamamoto M, Hayashi S et al (2014) Genetic variants in C5 and poor response to Eculizumab. N Engl J Med 370(7):632\u2013639. https:\/\/doi.org\/10.1056\/nejmoa1311084","journal-title":"N Engl J Med"},{"key":"8570_CR5","doi-asserted-by":"publisher","unstructured":"Obaid AH, Zografou C, Vadysirisack DD et al (2022) Heterogeneity of acetylcholine receptor Autoantibody-Mediated complement activity in patients with myasthenia Gravis. Neurol Neuroimmunol Neuroinflamm 9(4). https:\/\/doi.org\/10.1212\/NXI.0000000000001169","DOI":"10.1212\/NXI.0000000000001169"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08570-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08570-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08570-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:40:39Z","timestamp":1764895239000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08570-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":5,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["8570"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08570-4","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"3 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (protocol ID 6743).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The two involved patients have consented to the submission of their deidentified case reports and video material to the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained from the two patients. The two involved patients have consented to the submission of their deidentified case reports and video material to the journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"R.I. has received consultancy fees and speaker honoraria from Alexion, Argenx, UCB and Dianthus Therapeutics. Other authors declare no potential conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}